Table 3.

Association of the PS_GC with overall survival and disease-free survival in stage II and III patients receiving adjuvant chemotherapy

PSGC level	Adjuvant chemotherapy		Overall survival			Disease-free survival
	No chemo	Chemo	HR (95% CI)	P	Pinteraction	HR (95% CI)	P	Pinteraction
Training cohort (n = 199)
High PSGC (Chemo vs. No chemo)	29	90	0.748 (0.454–1.233)	0.255	0.001	0.840 (0.513–1.377)	0.490	<0.001
Low PSGC (Chemo vs. No chemo)	23	57	0.366 (0.136–0.786)	0.013		0.388 (0.165–0.914)	0.030
Validation cohort (n = 177)
High PSGC (Chemo vs. No chemo)	30	60	1.028 (0.639–1.657)	0.908	<0.001	1.203 (0.753–1.924)	0.439	<0.001
Low PSGC (Chemo vs. No chemo)	27	60	0.459 (0.221–0.955)	0.037		0.475 (0.231–0.979)	0.044
Total cohort (n = 376)
High PSGC (Chemo vs. No chemo)	59	150	0.834 (0.591–1.177)	0.302	<0.001	0.947 (0.675–1.329)	0.751	<0.001
Low PSGC (Chemo vs. No chemo)	50	117	0.392 (0.224–0.687)	0.001		0.434 (0.250–0.755)	0.003

Association of all variables with prognosis is analysed using a two-sided Cox proportional hazard regression analysis.

PS_GC pathomics signature of gastric cancer, HR hazard ratio, CI confidence interval, Chemo chemotherapy.